Companies › Hebei Senlang Biotechnology
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| S1904 CD19 CAR-T Autologous CD19-targeting CAR-T cells | – | Phase 2 | B-ALL | Mar 2027 |
| Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells Multi-target CAR-T cells targeting CD19, CD20, and CD22 | CD19, CD22, CD20 | Phase 1 | 19 and 22+ B Cell Hematologic Tumors | Mar 2027 |
| SENL101 CD7-targeting CAR-T cell therapy | CD7 | Phase 1 | T-lymphoblastic Lymphoma | Aug 2038 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05388695 | Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells | Phase 1 | 19 and 22+ B Cell Hematologic Tumors | Oncology | Mar 2027 |
| NCT07244406 | S1904 CD19 CAR-T | Phase 2 | B-ALL | Oncology | Mar 2027 |
| NCT06136364 | SENL101 | Phase 1 | T-lymphoblastic Lymphoma | Oncology | Aug 2038 |
Gilead Sciences AstraZeneca Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Roche Cellectis Lyell Immunopharma Amgen
PersonGen BioTherapeutics (Suzhou) Beijing Yongtai Ruike Biotechnology Company Allotera Therapeutics Hrain Biotechnology Marzieh Ebrahimi
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.